PubRank

Lisette Okkels Jensen

Author PubWeight™ 30.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010 2.53
2 Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009 2.40
3 Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013 2.39
4 Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010 2.38
5 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 2009 1.65
6 Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with ST-segment elevation myocardial infarction: from the Western Denmark heart registry. Catheter Cardiovasc Interv 2013 1.54
7 Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart 2013 1.47
8 Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry. Catheter Cardiovasc Interv 2012 1.38
9 Health care system delay and heart failure in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: follow-up of population-based medical registry data. Ann Intern Med 2011 1.12
10 Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2012 1.01
11 Between-centre reproducibility of volumetric intravascular ultrasound radiofrequency-based analyses in mild-to-moderate coronary atherosclerosis: an international multicentre study. EuroIntervention 2010 0.93
12 Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. Clin Epidemiol 2013 0.86
13 Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 2008 0.85
14 Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 2014 0.83
15 Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS). Int J Cardiol 2012 0.83
16 Comparison of outcomes of patients ≥ 80 years of age having percutaneous coronary intervention according to presentation (stable vs unstable angina pectoris/non-ST-segment elevation myocardial infarction vs ST-segment elevation myocardial infarction). Am J Cardiol 2011 0.82
17 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. JACC Cardiovasc Interv 2012 0.81
18 Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv 2014 0.79
19 The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. EuroIntervention 2012 0.78
20 Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients. Int J Cardiol 2011 0.78
21 Influence of high-dose lipid lowering treatment compared to low-dose lipid lowering treatment on plaque composition assessed by intravascular ultrasound virtual histology in patients with ST-segment elevation acute myocardial infarction: the VIRHISTAMI trial. EuroIntervention 2013 0.77
22 Sex and percutaneous coronary intervention. Lancet 2013 0.75
23 Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). BMC Cardiovasc Disord 2012 0.75
24 Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. BMC Cardiovasc Disord 2012 0.75
25 High sensitive C-reactive protein and interleukin 6 are not related to neointimal hyperplasia in paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study. Int J Cardiol 2006 0.75
26 Multicenter assessment of the reproducibility of volumetric radiofrequency-based intravascular ultrasound measurements in coronary lesions that were consecutively stented. Int J Cardiovasc Imaging 2012 0.75
27 Outcome and safety of same-day-discharge percutaneous coronary interventions with femoral access: a single-center experience. Am Heart J 2013 0.75
28 Quality assurance of the Western Denmark Heart Registry, a population-based healthcare register. Dan Med J 2017 0.75
29 Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial. Catheter Cardiovasc Interv 2013 0.75
30 Very late stent thrombosis caused by neoatherosclerotic plaque rupture. EuroIntervention 2015 0.75
31 Transient coronary aneurysm formation after Nevo™ stent implantation versus persistent coronary aneurysm after Cypher Select™ stent implantation. J Invasive Cardiol 2011 0.75
32 [C vitamin deficiency in alcoholics]. Ugeskr Laeger 2005 0.75
33 Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. Thromb Haemost 2016 0.75
34 Percutaneous biventricular cardiac assist device in cardiogenic shock and refractory cardiac arrest. EuroIntervention 2017 0.75